Case Report

Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia

Amer Aljundi,1 Alaa Rahhal,1 and Wafer Dabdoob2

1Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
2Cardiology and Cardiovascular Surgery Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar

Correspondence should be addressed to Alaa Rahhal; arahhal1@hamad.qa

Received 15 January 2020; Revised 23 May 2020; Accepted 2 June 2020; Published 10 June 2020

Academic Editor: Domingo A. Pascual Figal

Copyright © 2020 Amer Aljundi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case. We describe a case of a 62-year-old female patient admitted with acute ST-elevation myocardial infarction (STEMI) treated by primary coronary intervention (primary PCI) with a drug-eluting stent placement. She developed profound thrombocytopenia within 8 hours of first administration of eptifibatide and subsequent acute stent thrombosis next day. Other causes of thrombocytopenia were excluded and intravascular ultrasound (IVUS) showed good stent expansion and opposition to the coronary wall. Platelet count gradually returned to normal after discontinuation of eptifibatide. Conclusion. Although Eptifibatide has been associated with the development of thrombocytopenia, to the best of our knowledge, this is the first case report in the medical literature that associates acute stent thrombosis and eptifibatide-induced thrombocytopenia.

1. Introduction

There are several agents that are used in the treatment of acute coronary syndromes (ACS) that were reported to cause drug-induced thrombocytopenia [1, 2]. Eptifibatide is a synthetic cyclic heptapeptide and a selective inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that blocks the final common pathway of platelet aggregation. It is commonly used in patients with acute coronary syndromes and in those undergoing PCI to reduce the risk of acute cardiac ischemic events [3–6].

Recent literature has suggested an association between eptifibatide exposure and the development of thrombocytopenia. However, to the best of our knowledge, this is the first case report in the medical literature that associates acute stent thrombosis and eptifibatide-induced thrombocytopenia.

2. Case Presentation

A 62-year-old female with a history of diabetes mellitus and hypertension presented to the emergency department with a two-hour history of retrosternal chest pain radiating to both shoulders and associated with profuse sweating and vomiting. She denied any previous history of blood dyscrasia or thrombocytopenia. She had no history of drug abuse and denied any history of a previous hospitalization where she may have received heparin or eptifibatide. She does not have any known allergies. Her past medication history included the use of amlodipine 5 mg daily, atorvastatin 20 mg daily, metformin 500 mg daily, aspirin 100 mg daily, carvedilol 25 mg twice daily, and lisinopril 20 mg/hydrochlorothiazide 12.5 mg daily.

Vital signs at presentation included a temperature of 36.8°C, regular pulse of 98 bpm, brachial blood pressure of 140/70 mmHg, respirations of 20 per minute, and oxygen saturation of 98% on room air. The physical exam demonstrated an alert and oriented patient in moderate distress from chest pain. There were no signs of peripheral edema or cyanosis. The patient had bilateral basilar crackles at the bases. The heart was regular, with no murmurs, rubs, and gallops. The abdomen was soft with no organomegaly.

Her electrocardiogram (ECG) showed ST-segment elevation in lead II, III, aVF, Q wave in III, and reciprocal ST-
segment depression in I and aVL (Figure 1). Transthoracic echocardiography showed inferior left ventricular (LV) wall motion akinesia with normal LV systolic function (as demonstrated by an LV ejection fraction of 55-60%) and mild concentric LV hypertrophy. Other findings included a mild mitral regurgitation with normal other valves and chambers. At baseline, the patient had a white blood cell count of 12,000/mm3, a hemoglobin level of 13.9 g/dL, and a platelet count of 378,000/mm3. Cardiac markers were creatine kinase myoglobin (CK MB) level of 87.40 ng/ml and troponin T level of 4040 ng/mL. The values of prothrombin time (PT) and activated partial thromboplastin time (aPTT) were within normal limits. Similarly, liver function tests and kidney function tests were within normal limits.

Due to the patient’s ischemic symptoms and ECG changes consistent with an acute inferior STEMI, she was taken for urgent cardiac catheterization. Coronary angiography revealed a dominant RCA with a 99% stenosis with a thrombolysis in myocardial infarction (TIMI) grade 0 flow and a 40% stenosis of the left circumflex artery (LCx). Angiography also showed normal left main coronary artery (LMCA) and left anterior descending (LAD) coronary artery.

Following our local protocol, before catheterization, the patient received aspirin 300 mg; clopidogrel 600 mg; one dose of intravenous unfractionated heparin 7000 units; and eptifibatide 180 µg/kg as a bolus dose then 2 µg/kg/min infusion. A 3.0 x 24 mm XIENCE™ Everolimus Eluting Coronary stent was deployed in the distal RCA with a very satisfying angiographic result (TIMI grade 3 flow) with no complications. Once flow was restored in the RCA, the patient became pain-free with the resolution of her ST-segment elevation (Figure 2). She was then transferred in a stable condition to the coronary intensive care unit (CICU). Postpercutaneous coronary intervention (PCI) medications included dual antiplatelet therapy (DAPT) with aspirin 100 mg daily and clopidogrel 75 mg daily, ramipril 5 mg daily, metoprolol tartrate 25 mg twice daily, rosuvastatin 20 mg daily, and the eptifibatide intravenous infusion was to be continued for 18 hours.

Approximately eight hours post-PCI and eptifibatide initiation, the patient developed a profound thrombocytopenia, with her platelet count dropping by over 90% from baseline to 17,000/mm3. The rest of her complete blood count at this time included hemoglobin 13.2 g/dL, hematocrit 39.6%, and white blood cell count 18.8 x 10⁹/L. The platelet count trend included hemoglobin 13.2 g/dL, hematocrit 39.6%, and white blood cell count 18.8 x 10⁹/L. The platelet count trend showed no signs of platelet clumping. Moreover, there was no evidence of microangiopathic hemolytic anemia consistent with thrombotic thrombocytopenic purpura—hemolytic uremic syndrome (TTP-HUS) due to the administration of clopidogrel [10]. Additionally, other than thrombocytopenia, our patient did not manifest any other hallmarks of the disease which include fever, neurologic manifestations, and renal insufficiency. Moreover, our patient received only one loading dose of clopidogrel 600 mg six hours before the drop in her platelet count making it unlikely that clopidogrel was the culprit for the observed thrombocytopenia.

Use of the Naranjo scale to assess the probability of drug adverse events also indicated a probable relationship between the administration of eptifibatide and the development of profound thrombocytopenia (score of 5), while the relation was possible with heparin and clopidogrel (score 1) [11].

Heparin is well known to be associated with thrombocytopenia; however, the timing of thrombocytopenia in this patient was consistent with eptifibatide-induced thrombocytopenia as it occurred within less than 24 hours of starting eptifibatide. Heparin-induced thrombocytopenia (HIT) type I usually develops early within the first two days of starting heparin and is usually mild and transient (rarely <100,000 platelet/mm3). Heparin-induced thrombocytopenia type II, on the other hand, is an immune-mediated reaction with a typical onset of 5-10 days after the administration of heparin without previous heparin exposure and can be as early as hours due to circulating heparin/platelet factor 4 from a previous exposure [12]. Our patient had a severe form of thrombocytopenia ruling out HIT type I, while the time

3. Discussion

Eptifibatide is a potent adjunct medication that significantly improves outcomes in patients undergoing PCI among those presenting with ACS [3–6]. Eptifibatide works by preventing the binding of fibrinogen, von Willebrand factor, and other ligands to the GP IIb/IIIa receptor, thereby reversibly inhibiting platelet aggregation and subsequent thrombosis [1, 2]. Drug-induced acute profound thrombocytopenia can be defined as a decrease in platelet count to below 20,000/mm³ within 24 hours of exposure to the drug, which was the case in our patient having reached a low as 17,000/mm³ [7].

Our patient was exposed to several agents other than eptifibatide that are well known to be associated independently with profound thrombocytopenia, including heparin and clopidogrel [8]. These agents are usually coadministered before PCI which can make it difficult to discern causation in the setting of drug-induced thrombocytopenia.

Treatment with GP IIb/IIIa antagonists has been reported to be associated with pseudothrombocytopenia [9]. Pseud thrombocytopenia is an artificial laboratory process resulting from the adherence of platelets to leukocytes. This process typically occurs when blood samples are collected in EDTA tubes. Pseudothrombocytopenia in our scenario was ruled out by confirmation of thrombocytopenia in an EDTA-free tube and by direct review of the peripheral blood smear which showed no signs of platelet clumping. Moreover, there was no evidence of microangiopathic hemolytic anemia consistent with thrombotic thrombocytopenic purpura—hemolytic uremic syndrome (TTP-HUS) due to the administration of clopidogrel [10]. Additionally, other than thrombocytopenia, our patient did not manifest any other hallmarks of the disease which include fever, neurologic manifestations, and renal insufficiency. Moreover, our patient received only one loading dose of clopidogrel 600 mg six hours before the drop in her platelet count making it unlikely that clopidogrel was the culprit for the observed thrombocytopenia.

Use of the Naranjo scale to assess the probability of drug adverse events also indicated a probable relationship between the administration of eptifibatide and the development of profound thrombocytopenia (score of 5), while the relation was possible with heparin and clopidogrel (score 1) [11].

Heparin is well known to be associated with thrombocytopenia; however, the timing of thrombocytopenia in this patient was consistent with eptifibatide-induced thrombocytopenia as it occurred within less than 24 hours of starting eptifibatide. Heparin-induced thrombocytopenia (HIT) type I usually develops early within the first two days of starting heparin and is usually mild and transient (rarely <100,000 platelet/mm³). Heparin-induced thrombocytopenia type II, on the other hand, is an immune-mediated reaction with a typical onset of 5-10 days after the administration of heparin without previous heparin exposure and can be as early as hours due to circulating heparin/platelet factor 4 from a previous exposure [12]. Our patient had a severe form of thrombocytopenia ruling out HIT type I, while the time
frame for developing thrombocytopenia was not consistent 
with HIT type II as our patient had no previous exposure 
to heparin. Additionally, ELISA immunoassay was performed 
and was negative for heparin–platelet factor 4 antibodies. The 
patient’s platelet count started to improve after discontinuing 
eptifibatide. These factors suggested that eptifibatide was the 
most likely cause of thrombocytopenia associated with acute 
stent thrombosis.

The mechanisms by which GP IIb-IIIa inhibitors cause 
thrombocytopenia are poorly understood. One possible 
mechanism is the formation of antibodies to a group of 
epitopes, called ligand-induced binding sites (LIBSs), which 
are normally hidden on the surface of the platelet. Binding 
of the GP IIb-IIIa inhibitor to the receptor induces a confor-
mational change exposing LIBSs in the platelet. This permits 
the binding of the anti-LIBS antibodies and can eventually

**Figure 1:** Electrocardiogram (ECG) showing ST-segment elevation in lead II, III, aVF, Q wave in III, and reciprocal ST-segment depression in I and aVL at presentation.

**Figure 2:** ECG showing resolution of ST-segment elevation after PCI to RCA.

**Figure 3:** Platelet count during hospital stay.
lead to subsequent clearance of platelets by the reticuloendothelial system [13].

A proposed mechanism for thrombosis, however, is that LIBS antibodies can activate platelets by stabilizing the open, or active, conformation of the GP IIb/IIIa receptor, enabling the binding of multivalent ligands such as fibrinogen. Antibody-mediated fibrinogen binding can lead to bridging of adjacent platelets and platelet activation responses with subsequent generation of cell-surface procoagulant activity [14].

4. Conclusion

Eptifibatide is known to cause severe thrombocytopenia; however, this the first report of this being associated with subsequent acute stent thrombosis. Despite being uncommon, it is a clinically important complication of eptifibatide. This report highlights the importance of close monitoring platelet counts, before and after starting eptifibatide. A high index of suspicion of acute stent thrombosis should be raised.
if a patient develops new onset chest pain following successful PCI in the setting of eptifibatide-induced thrombocytopenia.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Consent**

A written informed consent for publishing patient’s information and images were obtained from the patient.

**Conflicts of Interest**

The authors declare that there is no conflict of interest.

**References**

[1] M. A. Rizvi, K. Kojouri, and J. N. George, “Drug-induced thrombocytopenia: an updated systematic review,” *Annals of Internal Medicine*, vol. 134, no. 4, 2001.

[2] R. H. Aster, “Drug-induced immune thrombocytopenia: an overview of pathogenesis,” *Seminars in Hematology*, vol. 36, 1 Suppl 1, pp. 2–6, 1999.

[3] J. E. Tcheng, “Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrin to Minimize Platelet Aggregation and Coronary Thrombosis,” *The American Journal of Cardiology*, vol. 80, no. 4, pp. 21B–28B, 1997.

[4] The PURSUIT Trial Investigators, “Inhibition of platelet glycoprotein IIb/IIa with Eptifibatide in patients with acute coronary syndromes,” *New England Journal of Medicine*, vol. 339, no. 7, pp. 436–443, 1998.

[5] The ESPRIT investigators, “Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial,” *The Lancet*, vol. 356, no. 9247, pp. 2037–2044, 2000.

[6] ADVANCE MI Investigators, “Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial,” *American Heart Journal*, vol. 150, no. 1, pp. 116–122, 2005.

[7] S. D. Berkowitz, R. A. Harrington, M. M. Rund, and J. E. Tcheng, “Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy,” *Circulation*, vol. 95, no. 4, pp. 809–813, 1997.

[8] I. E. Fahdi, J. F. Saucedo, T. Hennebry, M. Ghani, S. Sadanandan, and L. Garza-Arreola, “Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention,” *The American Journal of Cardiology*, vol. 93, no. 4, pp. 453–455, 2004.

[9] D. C. Sane, L. V. Damaraju, E. J. Topol et al., “Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy,” *Journal of the American College of Cardiology*, vol. 36, no. 1, pp. 75–83, 2000.

[10] C. L. Bennett, B. Kim, A. Zakarija et al., “Two mechanistic pathways for thienopyridine- associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project,” *Journal of the American College of Cardiology*, vol. 50, no. 12, pp. 1138–1143, 2007.

[11] C. A. Naranjo, U. Busto, E. M. Sellers et al., “A method for estimating the probability of adverse drug reactions,” *Clinical Pharmacology and Therapeutics*, vol. 30, no. 2, pp. 239–245, 1981.

[12] T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff, “Treatment and Prevention of Heparin-Induced Thrombocytopenia,” *Chest*, vol. 133, no. 6, pp. 340S–380S, 2008.

[13] M. Madan and S. D. Berkowitz, “Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors,” *American Heart Journal*, vol. 138, no. 4, pp. 5317–5326, 1999.

[14] C. Gao, B. Boylan, D. Bougie et al., “Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain,” *The Journal of Clinical Investigation*, vol. 119, no. 3, pp. 504–511, 2009.